Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Nanobodies uniquely possess the combined therapeutic advantages of mAbs and the targeting potential of nanoscale delivery. Their compact size enables enhanced tumor penetration and access to hidden and/or intracellular epitopes, while also granting high modularity for creating more complex constructs. Anti-EGFR (epidermal growth factor receptor) therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, demonstrate activity in a variety of tumor types.